8-KEarnings & ResultsSecurities & ListingExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2007)

Filed January 12, 2007For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on January 12, 2007, primarily to disclose a significant licensing and collaboration agreement with Inex Pharmaceuticals Corporation. This agreement grants Alnylam an exclusive worldwide license to Inex's liposomal delivery formulation technology, which is crucial for the discovery, development, and commercialization of RNAi therapeutics. This strategic move is aimed at enhancing Alnylam's capabilities in delivering its innovative RNA interference-based drugs. The financial terms involve an upfront payment of $8 million, to be made through the issuance of approximately 361,990 shares of Alnylam common stock, with a potential adjustment based on the stock's market value at a later date. Additionally, the filing addresses a potential share issuance to Novartis Pharma AG under an existing investor rights agreement. In response to the issuance of shares to Inex, Novartis has the right to purchase up to a certain number of Alnylam shares to maintain its percentage ownership. This could result in the issuance of up to approximately 70,431 shares to Novartis at a predetermined price. These share issuances are being conducted under exemptions from registration requirements, indicating a focus on strategic partnerships and capital management rather than a broad public offering at this time. Investors should note the impact of these potential share issuances on dilution and the company's financial structure.

Key Highlights

  • 1Alnylam Pharmaceuticals entered into a License and Collaboration Agreement with Inex Pharmaceuticals Corporation to exclusively license Inex's liposomal delivery formulation technology for RNAi therapeutics.
  • 2The agreement aims to enhance Alnylam's ability to deliver its RNAi-based drugs.
  • 3Alnylam will pay an upfront fee of $8 million to Inex, settled by issuing approximately 361,990 shares of Alnylam common stock on January 16, 2007.
  • 4There is a potential for a contingent cash payment to Inex based on the value of Alnylam shares if the initial share value is less than $8 million.
  • 5Novartis Pharma AG has a right to purchase up to approximately 70,431 shares of Alnylam common stock to maintain its ownership percentage due to the issuance to Inex.
  • 6The issuance of shares to Inex and potentially to Novartis will be conducted under an exemption from SEC registration requirements (Section 4(2)).
  • 7Alnylam reconfirmed its cash guidance for the year ended December 31, 2006, via a press release dated January 8, 2007.

Frequently Asked Questions

The primary purpose is for Alnylam Pharmaceuticals to gain an exclusive worldwide license to Inex's liposomal delivery formulation technology. This technology is critical for the development and commercialization of RNAi therapeutics, aiming to improve the delivery of Alnylam's drug candidates.

Alnylam is paying an upfront fee of $8 million to Inex. This is being settled by issuing approximately 361,990 shares of Alnylam common stock on January 16, 2007. There is also a potential for a future cash payment to Inex, dependent on the market value of the issued shares at a later date.

Novartis has a right to purchase shares, up to approximately 70,431 shares, to maintain its existing percentage ownership of Alnylam. This right is triggered by the issuance of shares to Inex. Whether Novartis exercises this right and purchases shares is not guaranteed.

No, the shares are being issued in reliance on an exemption from registration requirements under Section 4(2) of the Securities Act of 1933, which generally applies to transactions not involving a public offering. Alnylam will file an automatic resale registration statement for Inex to sell the shares.